AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer.
The company said it had initiated a trial of Calquence for treating cytokine storm associated with the disease. The drug is a BTK inhibitor approved for certain forms of leukemia and lymphoma, and the drugmaker said inhibiting BTK may have an effect on overactive immune responses.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica's pivotal trial.